Home › NDC Lookup › RxCUI directory › RxCUI 1243014

Axitinib 5 MG Oral Tablet [Inlyta] — RxCUI 1243014

RxNorm drug concept · Semantic branded drug
RxCUI 1243014 Semantic branded drug · SBD ● Current RxNorm concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1243014
Official nameAxitinib 5 MG Oral Tablet [Inlyta]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asInlyta 5 MG Oral Tablet
FDA products mapped4
Package NDCs mapped4
Reported Medicaid activity (SDUD)1,429 prescriptions · 20 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Axitinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Inlyta treats advanced kidney cancer (renal cell carcinoma). How you take it depends on your situation — your doctor may pair it with another cancer medicine called avelumab or pem...
  • What exactly is Inlyta used for, and will I take it alone or with other medicines?
  • You'll take Inlyta as a tablet twice a day, roughly 12 hours apart — morning and evening is a common routine. The good news is you can take it with or without food, so you have fle...
  • How do I take Inlyta — does it matter when or what I eat?
📖 Read our full Axitinib guide →

🕸️ Concept Web — How Axitinib 5 MG Oral Tablet [Inlyta] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Axitinib 5 MG Oral Tablet [Inlyta] RxCUI 1243014

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Axitinib 1242999
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Inlyta 1243005
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Axitinib Oral Tablet 1243003
    • Axitinib Oral Product 1243001
    • Axitinib Pill 1243002
    • Axitinib Oral Tablet [Inlyta] 1243007
    • Inlyta Oral Product 1243008
    • Inlyta Pill 1243009
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Axitinib 5 MG Oral Tablet SCD · 1243012
  • Axitinib 5 MG SCDC · 1243011
  • Axitinib Oral Tablet SCDF · 1243003
  • Axitinib Oral Product SCDG · 1243001
  • Axitinib Pill SCDG · 1243002

Brand-Name Concepts

  • Axitinib 5 MG [Inlyta] SBDC · 1243013
  • Axitinib Oral Tablet [Inlyta] SBDF · 1243007
  • Inlyta Oral Product SBDG · 1243008
  • Inlyta Pill SBDG · 1243009
  • Inlyta BN · 1243005

📦 FDA Products & Package NDCs

4 products · 4 package NDCs
4 package NDCs map to RxCUI 1243014 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00069-0145-01 180 TABLET, FILM COATED in 1 BOTTLE (0069-0145-01) INLYTA Pfizer Laboratories Div Pfizer Inc 2012-01-27
00069-0151-11 60 TABLET, FILM COATED in 1 BOTTLE (0069-0151-11) INLYTA Pfizer Laboratories Div Pfizer Inc 2012-01-27
63539-0026-01 90 TABLET, FILM COATED in 1 BOTTLE (63539-026-01) INLYTA U.S. Pharmaceuticals 2012-01-27
63539-0044-02 30 TABLET, FILM COATED in 1 BOTTLE (63539-044-02) INLYTA U.S. Pharmaceuticals 2012-01-27
Observed labelers: Pfizer Laboratories Div Pfizer Inc (2) · U.S. Pharmaceuticals (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.